Workflow
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
BCRXBioCryst Pharmaceuticals(BCRX) Benzinga·2025-05-05 21:29

Core Insights - BioCryst Pharmaceuticals reported first-quarter sales of 145.50million,a52.7145.50 million, a 52.7% increase year over year, surpassing the consensus estimate of 126.87 million [1] - The growth was primarily driven by Orladeyo's net revenue of 134.2million,whichincreasedby134.2 million, which increased by 45.3 million year over year, compared to 88.9millioninthesamequarterofthepreviousyear[1]FinancialPerformance−Thenetincomeforthefirstquarterof2025was88.9 million in the same quarter of the previous year [1] Financial Performance - The net income for the first quarter of 2025 was 32 thousand, or 0.00pershare,asignificantimprovementfromanetlossof0.00 per share, a significant improvement from a net loss of 35.4 million, or 0.17pershare,inthefirstquarterof2024[2]−Operatingincomeforthefirstquarterof2025was0.17 per share, in the first quarter of 2024 [2] - Operating income for the first quarter of 2025 was 21.2 million, compared to an operating loss of 14.5millionforthesameperiodin2024[3]−Non−GAAPoperatingincome,excludingstock−basedcompensation,was14.5 million for the same period in 2024 [3] - Non-GAAP operating income, excluding stock-based compensation, was 42.6 million for the first quarter of 2025, compared to a non-GAAP operating loss of 0.8millioninthefirstquarterof2024[3]GuidanceandOutlook−BioCrystraisedits2025revenueoutlookforOrladeyotobetween0.8 million in the first quarter of 2024 [3] Guidance and Outlook - BioCryst raised its 2025 revenue outlook for Orladeyo to between 580 million and 600million,upfromthepreviousestimateof600 million, up from the previous estimate of 535 million to 550million[4]−Thecompanynowanticipatesfull−year2025operatingexpensestobebetween550 million [4] - The company now anticipates full-year 2025 operating expenses to be between 440 million and 450million,anincreasefromthepriorguidanceof450 million, an increase from the prior guidance of 425 million to 435million[4]−Theexpectationforachievingnetincomeandpositivecashflowshasbeenacceleratedto2025,previouslyanticipatedfor2026[5]−Positivecashflowisdefinedastheimprovementincashandequivalentsfromyear−end2024toyear−end2025,excludinga435 million [4] - The expectation for achieving net income and positive cash flows has been accelerated to 2025, previously anticipated for 2026 [5] - Positive cash flow is defined as the improvement in cash and equivalents from year-end 2024 to year-end 2025, excluding a 75 million prepayment made in April 2025 [5] Market Reaction - Following the announcement, BCRX stock closed up by 23.50% to $11.03 [5]